Business Context and Reporting Period
SelectQuote, Inc. (SLQT) filed a Form 8-K on March 19, 2026, reporting a material event regarding its listing status on the New York Stock Exchange (NYSE). The company is incorporated in Delaware and operates from Overland Park, Kansas.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the market price of the company's common stock, which averaged less than $1.00 per share over a consecutive 30-trading-day period, triggering the delisting notice.
Material Changes
The primary material change is the receipt of a notice from the NYSE indicating non-compliance with Section 802.01C of the NYSE Listed Company Manual due to the low stock price. The company's stock remains listed and traded during the cure period, but failure to regain compliance could result in delisting.
Guidance, Outlook, and Risks
- Cure Plan: The company intends to notify the NYSE of its intent to cure the deficiency. It has a six-month cure period to regain compliance.
- Compliance Criteria: To cure the deficiency, the stock must close at or above $1.00 on the last trading day of any calendar month within the cure period and maintain an average closing price of at least $1.00 over the preceding 30 trading days.
- Alternative Actions: The company may consider alternatives to cure the deficiency, which could include actions requiring stockholder approval. If such actions are taken, the price condition is cured if the stock price promptly exceeds $1.00 and remains above that level for 30 trading days.
- Risks: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to the company's ability to regain compliance and other factors detailed in its Form 10-K.
Investor Verification Checklist
- Verify the current trading price of SLQT to assess the likelihood of meeting the $1.00 threshold within the six-month cure period.
- Monitor for any press releases or filings regarding specific corporate actions (e.g., reverse stock splits) intended to cure the deficiency.
- Review the company's most recent Form 10-K for detailed risk factors and financial health context not present in this 8-K.
- Confirm the exact expiration date of the six-month cure period to understand the timeline for potential delisting.